Hinge Health stock has almost doubled year to date, yet the valuation checks still lean expensive, so investors are weighing strong recent gains against a relatively weak value score.

• Hinge Health has returned 95.4% year to date, which puts extra focus on whether the current share price already reflects much of the good news.
• The planned US$105 million acquisition of Cylinder Health and expansion into gastrointestinal care may support higher growth expectations. At the same time, execution risk around integrating new programs and controlling costs can weigh on what investors are willing to pay.
• With a value score of 2 out of 6, the stock currently does not screen as a clear bargain on the broader valuation checks.

The issue now is whether Hinge Health's recent share price strength leaves enough potential upside to justify paying this kind of valuation today.

Has Hinge Health Run Too Far on Earnings?

P/E is useful for Hinge Health because the company is generating positive earnings, so you can compare what the market pays for each dollar of profit. Right now the stock trades at about 66.9x earnings, which is very close to the peer average of 66.3x but far above the broader Healthcare sector on 24.7x. That indicates investors are already paying a premium for Hinge Health relative to the wider industry.

The fair P/E ratio implied by the model is 38.0x, which is well below the current 66.9x level. Even with interest in Hinge Health rising after the planned Cylinder Health acquisition and GI expansion, the gap to this fair multiple suggests the stock is pricing in a lot of optimism. Within this framework, the shares appear expensive compared with what the company’s profile would usually justify.

On the P/E multiple, Hinge Health stock currently screens as overvalued.

The Hinge Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Hinge Health pick up where the current P/E puzzle leaves off. They spell out which growth, margin and earnings paths would need to occur for the stock to be worth materially more or less than today's price. Each narrative ties a fair value estimate to a clear story about Hinge Health's potential catalysts and risks, so you can track over time which version of events appears closer to reality on the Community page.

Community views on Hinge Health sit far apart, with some investors focused on the multi condition platform upside while others worry about how much optimism is already in the price.

Bull case: 35% undervalued

"AI powered care tools and the Robin assistant allowed Hinge Health to serve 47% more members in 2025 while keeping care team costs flat…"

Bear case: 37% overvalued

"Although the move to engagement based pricing is aligned with client interests and current average selling price is essentially flat, the model ties revenue more tightly to actual member usage…"

Do you think there's more to the story for Hinge Health? Head over to our Community to see what others are saying!

The Bottom Line

Hinge Health looks overvalued on current market multiples, which already price in a lot of optimism about the business. With a low value score, the broader checks are not giving a clear margin of safety at today’s levels. For buyers and holders, the key question is whether Hinge Health can deliver the growth, margins, and successful integration of Cylinder Health that would keep investors comfortable paying this kind of premium.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.